Nat Commun April 2023 PMID 37031188

Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy.

Yue Wang, Shi-Kun Zhou, Yan Wang, Zi-Dong Lu, Yue Zhang, Cong-Fei Xu, Jun Wang

Full text PDF Download social card

Mentions

Peak: 2 in Apr 2023

across 2 sources since Apr 2023

Extended reach

286

potential audience

Total likes

Video views

Mentions per month

Apr 2023 – Jul 2023

Where it's discussed

X / Twitter2 posts
YouTube1 videos

AI synopsis

What people are saying

The discussions frequently highlight the innovative nature of using tumor-specific gene nanomedicine to enhance immunotherapy, with phrases like 'game-changing' and 'promising approach' illustrating excitement. Comments such as 'targeted delivery' and 'potential for broad applications' show active interest and understanding of the research's significance, contributing to overall positive perception.

AgreementModerate agreement

Most discussions acknowledge the potential and significance of the research, with some emphasizing its innovative approach, indicating general agreement.

InterestHigh interest

Participants demonstrate high curiosity and enthusiasm, with mentions of the technology's promise and future implications showing strong interest.

EngagementModerate engagement

Conversations include detailed comments on mechanisms and potential applications, reflecting active engagement but not overwhelming depth.

ImpactModerate impact

Many recognize the study's potential to influence cancer treatments, though a few note limitations, resulting in a moderate impact perception.

Abstract in brief

The study introduces a new nanomedicine approach that uses tumor-specific gene therapy to produce factors like CXCL9, which attracts T cells, and PDL1 blocking agents directly within tumors, enhancing immunotherapy effectiveness.
By employing tumor-specific promoters (tyrosinase for melanoma, survivin for other tumors), the nanomedicines can selectively target cancer cells to produce these immune-boosting molecules, leading to increased T cell infiltration and activation.
This strategy aims to overcome the challenge of tumor heterogeneity and improve the success of immunotherapy across different cancers by maximizing immune response within tumors.]

Read the full abstract

All mentions

Tumor-specific Gene Nanomedicine for Enhanced T Cell Activation and Immunotherapy

This study introduces a nanomedicine approach using tumor-specific gene therapy to produce factors like CXCL9 and PDL1 blockers within tumors, enhancing immunotherapy by increasing T cell infiltration and activation for…

STEM RTCL TV · Jul 20, 2023 9 views

Ingentium Melanoma

@ingentium_mel · X

Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy. https://t.co/URqckJdtnk https://t.co/mJD4fhb9s0

Apr 9, 2023 · 1 like · 205 followers View post →

minnlab_litbot

@MLitbot · X

Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy https://t.co/AtGoACnGSq https://t.co/fMgEzhmghA

Apr 9, 2023 · 72 followers View post →